The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Invus Advisors, L.l.c. since 2015.
This trader's CIK number is 1404553.
At the time of last reporting, Invus Advisors, L.l.c. was the Officer of Lexicon Pharmaceuticals, Inc.. (stock ticker symbol LXRX).
Also see all insider trading activities at Lexicon Pharmaceuticals, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2024 | LXRX | 0 | $0 | 0 | $0 | 57,546,100 | $0 |
| 2023 | LXRX | 27,775,050 | $72,215,130 | 0 | $0 | 0 | $0 |
| 2022 | LXRX | 16,173,800 | $40,434,500 | 0 | $0 | 0 | $0 |
| 2020 | LXRX | 10,937,500 | $35,000,000 | 0 | $0 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2016 | BUFF | 0 | $0 | 27,526,672 | $630,223,156 | 0 | $0 |
| 2015 | BUFF | 0 | $0 | 28,464,603 | $569,292,060 | 0 | $0 |
1. Lexicon Pharmaceuticals, Inc. (LXRX)
2. Blue Buffalo Pet Products, Inc. (BUFF)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-05-10 | LXRX | Option Ex | 57,546,100 | .00 | 0 |
| 2023-06-05 | LXRX | Buy | 27,775,050 | 2.60 | 72,215,130 |
| 2022-08-01 | LXRX | Buy | 16,173,800 | 2.50 | 40,434,500 |
| 2020-12-16 | LXRX | Buy | 10,937,500 | 3.20 | 35,000,000 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2016-09-16 | BUFF | Sale | 12,512,124 | 24.83 | 310,638,502 |
| 2016-07-05 | BUFF | Sale | 15,014,548 | 21.29 | 319,584,654 |
| 2015-07-27 | BUFF | Sale | 28,464,603 | 20.00 | 569,292,060 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Invus Advisors, L.l.c. (Officer of Lexicon Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.